Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity-Reference-Cited by-同舟云学术

Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity

Published:2024-07-02 Issue:1 Volume:44 Page:
ISSN:1573-2630
Container-title:International Ophthalmology
language:en
Short-container-title:Int Ophthalmol

Author:

Sabancı Şenol,Küçük Mehmet Fatih,Süren Elçin,Erol Muhammet Kazim

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10792-024-03171-0.pdf

Reference28 articles.

1. Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123(9):1845–1855. https://doi.org/10.1016/j.ophtha.2016.04.028

2. Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmström G (2013) Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 91(2):170–175. https://doi.org/10.1111/j.1755-3768.2011.02351.x

3. Drenser KA, Trese MT, Capone A Jr (2010) Aggressive posterior retinopathy of prematurity. Retina 30:S37-40. https://doi.org/10.1097/iae.0b013e3181cb6151

4. Funatsu H, Hori S, Yamashita H, Kitano S (1996) Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy. Nippon Ganka Gakkai Zasshi 100(5):339–349

5. González Viejo I, Ferrer Novella C, Pueyo Royo V (2011) Uso de anti-VEGF (anti-vascular endothelial growth factor) en la retinopatía del prematuro [use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP)]. Arch Soc Esp Oftalmol 86(7):207–208. https://doi.org/10.1016/j.oftal.2011.05.008